Allergan calls a cease-fire after thousands of job cuts at its HQ

Allergan ($AGN), still working through its $66 billion merger with Actavis, is through shedding jobs at its California headquarters, CEO Brent Saunders said, moving on from laying off more than 1,000 workers over the past year. The company's Irvine, CA, home base has been repeatedly downsized as Allergan worked to fend off unwanted attention from Valeant Pharmaceuticals ($VRX) and again after Actavis won the bidding war. Now, however, "the cuts are done," Saunders told the LA Times. "There is no second shoe to drop. The people who are there are there." More from FiercePharma

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.